Boston Scientific Corporation Q2 2026 Earnings Recap

Boston Scientific's shares were essentially unchanged (-0.1%) as the quarter showed steady organic sales growth and solid margins, but the market digested cautious guidance revisions driven by softness in WATCHMAN and electrophysiology (EP) segments.

Key Takeaways

• Q2 organic revenue grew 7%, driven by Interventional Cardiology, Endoscopy, and Neuromodulation, within prior full-year guidance range.
• Adjusted EPS of $0.86 rose 15%, aided by favorable tax outcomes, and operating margin was healthy at 28.4%.
• Guidance trimmed: full-year organic growth now expected at 5%-6%, below previous midpoint; adjusted EPS growth moderation reflected in narrowed $3.28-$3.32 range.
• Key headwinds in WATCHMAN (clinical evidence impacting referrals) and EP (unexpected share loss in U.S.) pressured outlook; these segments weigh on near-term growth.
• Restructuring plan announced to deliver $500 million in run-rate savings by 2029, aiming to offset pressures and underpin improved growth in 2028 and beyond.